Stock TRAW TRAWS PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
0.6044 USD -2.62% Intraday chart for Traws Pharma, Inc. -5.52% -18.94%
May. 07 Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy CI
Apr. 04 North American Morning Briefing : Focus Turns to -2- DJ

Strengths

  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The opinion of analysts covering the stock has improved over the past four months.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
TRAWS PHARMA, INC. Stock Traws Pharma, Inc.
-18.94% 13.09M -
MODERNA, INC. Stock Moderna, Inc.
+54.05% 63.85B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.02% 41.83B
B
LONZA GROUP AG Stock Lonza Group AG
+40.01% 40.47B
A
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.17B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.42% 26.52B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.60% 18.69B
B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.89% 12.73B
B+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.40% 12.11B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.49% 12.07B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TRAW Stock
  4. Ratings Traws Pharma, Inc.